There’s a new surgical robot in town. Da Vinci, meet Senhance.
TransEnterix shareholders have every reason to be excited. The U.S. Food and Drug Administration cleared the way for the company to market its Senhance Surgical Robotic System on Friday. TransEnterix held a conference call to discuss the big news on Monday morning, with its stock skyrocketing on the announcement.
Senhance will become the first system to compete head-to-head against Intuitive Surgical‘s da Vinci system, which first launched back in 2000.
